Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Associations between lifetime classic psychedelic use and markers of physical health
Otto Simonsson, James Sexton, Peter S. Hendricks
Journal of Psychopharmacology (2021) Vol. 35, Iss. 4, pp. 447-452
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics
Otto Simonsson, Peter S. Hendricks, Richard Chambers, et al.
Journal of Affective Disorders (2023) Vol. 326, pp. 105-110
Open Access | Times Cited: 74
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample
Victoria Amalie Nygart, Lis Marie Pommerencke, Eline Haijen, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 8, pp. 932-942
Open Access | Times Cited: 51
Personal Psychedelic Use Is Common Among a Sample of Psychedelic Therapists: Implications for Research and Practice
Jacob S. Aday, Zachary Skiles, Noa Eaton, et al.
Psychedelic Medicine (2023) Vol. 1, Iss. 1, pp. 27-37
Closed Access | Times Cited: 40
Pattern breaking: a complex systems approach to psychedelic medicine
Inês Hipólito, Jonas Mago, Fernando Rosas, et al.
Neuroscience of Consciousness (2023) Vol. 2023, Iss. 1
Open Access | Times Cited: 39
Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment
Jenessa N. Johnston, Bashkim Kadriu, Josh Allen, et al.
Neuropharmacology (2023) Vol. 226, pp. 109422-109422
Open Access | Times Cited: 32
Perceived Risk of Trying Lysergic Acid Diethylamide in the United States from 2015 to 2019: Are Americans Assessing Lysergic Acid Diethylamide's Risk Profile More Favorably?
Brian S. Barnett, Akhil Anand, Elizabeth N. Dewey, et al.
Psychedelic Medicine (2024) Vol. 2, Iss. 2, pp. 74-86
Closed Access | Times Cited: 9
Psychedelics, Sociality, and Human Evolution
José Manuel Rodríguez Arce, Michael Winkelman
Frontiers in Psychology (2021) Vol. 12
Open Access | Times Cited: 49
Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States
Otto Simonsson, Simon B. Goldberg
Journal of Psychoactive Drugs (2022) Vol. 55, Iss. 1, pp. 11-18
Open Access | Times Cited: 33
Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes
Grant Jones, Matthew K. Nock
Journal of Psychopharmacology (2022) Vol. 36, Iss. 1, pp. 57-65
Closed Access | Times Cited: 31
Psychedelic Mushrooms in the USA: Knowledge, Patterns of Use, and Association With Health Outcomes
Richard Matzopoulos, Robert Morlock, Amy Morlock, et al.
Frontiers in Psychiatry (2022) Vol. 12
Open Access | Times Cited: 30
Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics
Alaina M. Jaster, Javier González‐Maeso
Molecular Psychiatry (2023) Vol. 28, Iss. 9, pp. 3595-3612
Open Access | Times Cited: 22
Therapeutic modulation of the kynurenine pathway in severe mental illness and comorbidities: A potential role for serotonergic psychedelics
Antonella Campanale, Antonio Inserra, Stefano Comai
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2024) Vol. 134, pp. 111058-111058
Open Access | Times Cited: 6
Unraveling psilocybin’s therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression
Magdalena Kolasa, Agnieszka Nikiforuk, Agata Korlatowicz, et al.
Psychopharmacology (2024)
Open Access | Times Cited: 6
Associations between lifetime classic psychedelic use and cardiometabolic diseases
Otto Simonsson, Walter Osika, Robin Carhart‐Harris, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 37
Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice
Nicole Fadahunsi, Jens Lund, Alberte Wollesen Breum, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 26
Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling
Jack E. Henningfield, Marion A. Coe, Roland R. Griffiths, et al.
Neuropharmacology (2022) Vol. 218, pp. 109220-109220
Open Access | Times Cited: 25
Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis
Haley Maria Dourron, Camilla K. Strauss, Peter S. Hendricks
Pharmacological Reviews (2022) Vol. 74, Iss. 4, pp. 984-1029
Open Access | Times Cited: 23
A role for the serotonin 2A receptor in the expansion and functioning of human transmodal cortex
Andrea I. Luppi, Manesh Girn, Fernando Rosas, et al.
Brain (2023) Vol. 147, Iss. 1, pp. 56-80
Open Access | Times Cited: 14
Psychedelic use and psychiatric risks
Otto Simonsson, Simon B. Goldberg, Richard Chambers, et al.
Psychopharmacology (2023)
Open Access | Times Cited: 13
Minorities’ diminished psychedelic returns: Cardio-metabolic health
Sean Matthew Viña
Drug Science Policy and Law (2024) Vol. 10
Open Access | Times Cited: 5
Diminished psychedelic returns on distress: Marital status and household size
Sean M. Viña
PLoS ONE (2024) Vol. 19, Iss. 3, pp. e0293675-e0293675
Open Access | Times Cited: 5
Psychedelics in the treatment of unipolar and bipolar depression
Oliver G. Bosch, Simon Halm, Erich Seifritz
International Journal of Bipolar Disorders (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 19
Psychedelics and workplace harm
Sean Matthew Viña, Amanda Layne Stephens
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 12
Classic Psychedelic Use and Current Meditation Practice
Charlotta Simonsson, Richard Chambers, Peter S. Hendricks, et al.
Mindfulness (2023) Vol. 14, Iss. 4, pp. 763-768
Open Access | Times Cited: 11
Minorities’ diminished psychedelic returns
Sean M. Viña, Amanda L Stephens
Drug Science Policy and Law (2023) Vol. 9
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top